Series of aminopyridinecarboxamide-based inhibitors were synthesized and tested against human recombinant IKK-2 and in IL-1 beta stimulated synovial. broblasts. The 2-amino-5-chloropyridine-4-carboxamides were identified as the most potent inhibitors with improved cellular activity. (C) 2009 Elsevier Ltd. All rights reserved.
作者:Dominique F. Bonafoux、Sheri L. Bonar、Michael Clare、Ann M. Donnelly、Jeanette L. Glaenzer、Julia A. Guzova、He Huang、Nandidni N. Kishore、Francis J. Koszyk、Patrick J. Lennon、Adam Libby、Sumathy Mathialagan、David S. Oburn、Sharon A Rouw、Cynthia D. Sommers、Catherine S. Tripp、Lori J. Vanella、Richard Weier、Serge G. Wolfson、Horng-Chih Huang
DOI:10.1016/j.bmc.2009.10.040
日期:2010.1
Series of aminopyridinecarboxamide-based inhibitors were synthesized and tested against human recombinant IKK-2 and in IL-1 beta stimulated synovial. broblasts. The 2-amino-5-chloropyridine-4-carboxamides were identified as the most potent inhibitors with improved cellular activity. (C) 2009 Elsevier Ltd. All rights reserved.
Substituted pyrazolyl compounds for the treatment of inflammation
申请人:Bergmanis A. Arija
公开号:US20050256180A1
公开(公告)日:2005-11-17
The present invention relates to substituted pyrazolyl derivatives, compositions comprising such, intermediates, methods of making substituted pyrazolyl derivatives, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.